ESPR
Esperion Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.18
+0.00%Margins
Gross margin
65.0%
EBITDA margin
9.5%
EBIT margin
18.1%
Net margin
-1.8%
FCF margin
-4.3%
2.4%
Return on equity
-1.6%
Return on assets
32.1%
Return on invested capital
0.90x
Asset turnover
-$18.2M
Cash from operations
$0.61
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026